Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to <scp>BCMA</scp> ‐Targeted Bispecifics and High‐Dose Melphalan
TAL-associated taste disturbances have a major impact on patients and require further investigation and mitigation strategies. Enhanced patient support, proactive monitoring, and targeted interventions are critical to improving the well-being and adherence of MM patients.
Authors
- Anna Fleischer (ORCID: https://orcid.org/0009-0009-8760-3931)
- Imad Maatouk (ORCID: https://orcid.org/0000-0002-8030-1182)
- Leo Rasche (ORCID: https://orcid.org/0000-0002-9536-9649)
- Jan Frenking (ORCID: https://orcid.org/0009-0001-9682-2601)
- Christine Riedhammer (ORCID: https://orcid.org/0009-0008-7106-7217)
- Jessica Peter
- Götz Gelbrich
- K. Martin Kortüm (ORCID: https://orcid.org/0000-0002-7011-0286)
- Marc S. Raab (ORCID: https://orcid.org/0000-0003-4181-6922)
- Patrick‐Pascal Strunz (ORCID: https://orcid.org/0000-0002-3168-7074)
- Franziska Panther
- Johannes M. Waldschmidt (ORCID: https://orcid.org/0000-0001-5340-1818)
- Julia Mersi (ORCID: https://orcid.org/0009-0008-7651-8080)
- Hermann Einsele
- M. Roll
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Universitätsklinikum Würzburg (DE)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/cam4.71401
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- Deutsche Krebshilfe